Breast Implant-Associated Anaplastic Large-Cell Lymphoma (BIA-ALCL): Managing New and Current Patients, Reducing Risk


Release Date: April 30, 2022
Expiration Date: April 30, 2023
Time to Complete Activity: 1.25 hours

Steering Committee
William P. Adams Jr, MD

Associate Professor of Plastic Surgery
Program Director Aesthetic Fellowship UTSW
UT Southwestern Medical Center
Dallas, TX
Immediate Past President
The Aesthetic Societ
Past President
Aesthetic Surgery Education and Research Foundation (ASERF)

Caroline A. Glicksman, MD, MSJ
Clinical Assistant Professor
Hackensack Meridian School of Medicine
Nutley, NJ
Glicksman Plastic Surgery
Sea Girt, NJ
Co-Chair ASERF Scientific Research Committee
Secretary
ASERF Board of Directors

Patricia A. McGuire, MD, FACS
Clinical Instructor of Surgery
Washington University School of Medicine
Private Practice Plastic Surgery
St. Louis, MO
ASERF Board of Directors

Target Audience
This activity has been designed to address the educational needs of plastic surgeons, primary care clinicians, and other healthcare providers who are involved in the management of patients with BIA-ALCL.

This activity is jointly provided by Paradigm Medical Communications, LLC, American Association of Nurse Practitioners, and American Academy of Physician Associates.
  

In collaboration with International Society of Aesthetic Plastic Surgery. 

Description BIA-ALCL is a rare type of lymphoma associated with textured, but not smooth, breast implants. As of April 2020, there were approximately 800 BIA-ALCL cases worldwide, including 33 BIA-ALCL–related deaths. When detected early, BIA-ALCL is curable in most patients with proper treatment. However, although BIA-ALCL has been recognized by the World Health Organization since 2016, many primary care practitioners (PCPs) and plastic surgeons are not fully aware of how to detect and diagnose BIA-ALCL, as well as recommended treatment strategies for this disease. There is therefore an unmet need for continuing education to better educate PCPs and plastic surgeons on how to diagnose, stage, and optimally treat BIA-ALCL, as well as how to better educate their patients about the importance of early detection and appropriate treatment.

Learning Objectives
At the conclusion of this activity, participants should be able to:
  • Describe possible complications of textured breast implants, including the symptoms and relative risk of BIA-ALCL and benefits of early identification and treatment
  • Create protocols for appropriate management of asymptomatic patients with textured implants as well as surgical protocols to reduce risk of BIA-ALCL
  • Devise an effective plan to educate and communicate with patients who have implants about BIA-ALCL, its early signs and symptoms, and the association of early detection with prognosis

Accreditation Statement
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Paradigm Medical Communications, LLC, American Association of Nurse Practitioners, and American Academy of Physician Associates. Paradigm Medical Communications, LLC is accredited by the ACCME to provide continuing medical education for physicians.
 
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Designation Statement
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid through April 30, 2023.

AANP Credit Designation Statement
This activity is approved for 1.25 contact hour(s) of continuing education by the American Association of Nurse Practitioners®. Activity ID# 22045462. This activity was planned in accordance with AANP Accreditation Standards and Policies.
 

Instructions for Participation
To receive a certificate of participation, participants must:

  • Follow instructions to register or log in with your professional information and complete the preassessment  
  • View the online activity in its entirety
  • Complete and submit the online postassessment and evaluation. You must answer 70% of the postassessment questions correctly to earn credit. You will have unlimited opportunities to successfully complete the postassessment. 


A certificate of participation will be available for download/printing immediately following your successful completion of the postassessment and evaluation.  

For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com.

There are no fees for participating in this activity.

Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.

All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated.

All individuals in a position to control the content of this activity have disclosed all financial relationships with ineligible companies during the past 24 months. All disclosures are listed below.

Faculty
William P. Adams Jr, MD
Stocks: Tepha Inc (expired 7/21)

Caroline A. Glicksman, MD, MSJ
Other: Establishment Labs S.A. (Clinical Trial)

Patricia A. McGuire, MD, FACS
Consultant: Establishment Labs S.A.

AAPA Staff
Michele Hoang, Cheryl Holmes, and Eric Peterson have no relevant financial relationships to disclose.

Paradigm Staff
Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.

Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.

AANP Staff
Michele McKay, MSN, APRN, FNP-C, CHCP has no relevant financial relationships with ineligible companies to disclose.

Disclaimers
The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients.

Off-Label/Unapproved Product(s) Discussion
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

Acknowledgement of Commercial Support
This activity is supported by an educational grant from AbbVie Inc.

Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.